Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous s stock reports and market updates.
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) shares gained 0.17 percent to close at $11.48 a share Monday. The stock traded between $11.21 and $12.00 on volume of 912,501 shares traded. Analysts at H.C. Wainwright have recently initiated coverage on the company with a “buy” rating and a price target of $21.00. Shares of the BioCryst Pharmaceuticals have gained approximately 50.0 percent year-to-date.
Find out more about BioCryst Pharmaceuticals including full access to the free equity report at:
www.RDInvesting.com/BCRX
Eagle Pharmaceuticals Inc. (NASDAQ: EGRX) shares declined 0.20 percent to close at $14.89 a share Monday. The stock traded between $14.66 and $15.34 on volume of 457,326 shares traded. Analysts at William Blair have recently initiated coverage on the company with an “outperform” rating and a price target of $22.00. Shares of the Eagle Pharmaceuticals have gained approximately 16.0 percent year-to-date.
Find out more about Eagle Pharmaceuticals including full access to the free equity report at:
www.RDInvesting.com/EGRX
Flexion Therapeutics Inc. (NASDAQ: FLXN) shares declined 0.21 percent to close at $19.22 a share Monday. The stock traded between $18.57 and $19.99 on volume of 170,854 shares traded. Analysts at Needham have recently initiated coverage on the company with a “buy” rating and a price target of $26.00. Shares of the Flexion Therapeutics have gained approximately 30.0 percent year-to-date.
Find out more about Flexion Therapeutics including full access to the free equity report at:
www.RDInvesting.com/FLXN
Seattle Genetics, Inc. (NASDAQ: SGEN) shares declined 0.33 percent to close at $51.61 a share Monday. The stock traded between $50.40 and $52.91 on volume of 718,461 shares traded. Analysts at H.C. Wainwright have recently initiated coverage on the company with a “buy” rating and a price target of $65.00. Shares of the Seattle Genetics have gained approximately 30.0 percent year-to-date.
Find out more about Seattle Genetics including full access to the free equity report at:
www.RDInvesting.com/SGEN
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Research Driven Investing
[email protected]